These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 6101571)

  • 1. Dose reduction and discontinuation of antipsychotic medication.
    Kurucz J; Fallon J
    Hosp Community Psychiatry; 1980 Feb; 31(2):117-9. PubMed ID: 6101571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prescription of discretionary antipsychotic medication by state mental hospital psychiatrists.
    Benson PR
    J Health Soc Behav; 1986 Mar; 27(1):28-43. PubMed ID: 2872249
    [No Abstract]   [Full Text] [Related]  

  • 3. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using an explicit guideline-based criterion and implicit review to assess antipsychotic dosing performance for schizophrenia.
    Owen RR; Thrush CR; Hudson TJ; Mallory SR; Fischer EP; Clardy JA; Williams DK
    Int J Qual Health Care; 2002 Jun; 14(3):199-206. PubMed ID: 12108530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.
    Walthour A; Seymour L; Tackett R; Perri M
    Ann Pharmacother; 2010 May; 44(5):809-18. PubMed ID: 20388858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.
    Ascher-Svanum H; Nyhuis AW; Stauffer V; Kinon BJ; Faries DE; Phillips GA; Schuh K; Awad AG; Keefe R; Naber D
    Curr Med Res Opin; 2010 Oct; 26(10):2403-10. PubMed ID: 20812791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
    Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
    CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a schizophrenia medication algorithm in a state hospital.
    Chuang WC; Crismon ML
    Am J Health Syst Pharm; 2003 Jul; 60(14):1459-67. PubMed ID: 12892030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of antipsychotic treatment for schizophrenia in Hong Kong.
    Yip KC; Ungvari GS; Cheung HK; Ng FS; Lau ST
    Chin Med J (Engl); 1997 Oct; 110(10):792-6. PubMed ID: 9642312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
    BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
    Tiihonen J; Tanskanen A; Taipale H
    Am J Psychiatry; 2018 Aug; 175(8):765-773. PubMed ID: 29621900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent medication for schizophrenic outpatients: who is eligible?
    Chiles JA; Sterchi D; Hyde T; Herz MI
    Schizophr Bull; 1989; 15(1):117-21. PubMed ID: 2566198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro re nata medication for psychoses: an audit of practice in two metropolitan hospitals.
    Geffen J; Sorensen L; Stokes J; Cameron A; Roberts MS; Geffen L
    Aust N Z J Psychiatry; 2002 Oct; 36(5):649-56. PubMed ID: 12225449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicians' reasons not to discontinue long-term used off-label antipsychotic drugs in people with intellectual disability.
    de Kuijper GM; Hoekstra PJ
    J Intellect Disabil Res; 2017 Oct; 61(10):899-908. PubMed ID: 28560761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.